Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828015) titled 'Bevacizumab in the Treatment of HHT' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Condition:
Bevacizimab
HHT
Intervention:
Drug: Bevacizumab
Procedure: nasal electrocoagulation.
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: May 1, 2025
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT078280...